A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6280 When Given in Multiple Ascending Oral Doses in Healthy Male and Healthy Female Subjects of Non-Child Bearing Potential

Trial Profile

A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6280 When Given in Multiple Ascending Oral Doses in Healthy Male and Healthy Female Subjects of Non-Child Bearing Potential

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Dec 2010

At a glance

  • Drugs AZD 6280 (Primary)
  • Indications Anxiety disorders
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 08 Dec 2010 Actual end date changed from 1 Sep 2008 to 1 Jul 2008 as reported by ClinicalTrials.gov.
    • 08 Dec 2010 Actual initiation date changed from 1 Apr 2008 to 1 Mar 2008 as reported by ClinicalTrials.gov.
    • 20 Nov 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top